stockrowVaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) Return on invested capital
Vaxcyte, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −57.3%, down 6.0 percentage points from fiscal 2025 (−51.3%). Over the past ten years it has ranged from −652.8% (fiscal 2022) to 0.00% (fiscal 2020); the current reading is higher than 50% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −51.3% | (28.50) |
| FY2024 | −22.8% | 159.71 |
| FY2023 | −182.6% | 470.24 |
| FY2022 | −652.8% | (482.50) |
| FY2021 | −170.3% | (170.29) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PTGX Protagonist Therapeutics, Inc. compare | 61.8% |
| CAI Caris Life Sciences,�Inc. compare | 22.2% |
| TGTX TG Therapeutics, Inc. compare | 10.7% |
| TECH Bio-Techne Corp compare | 7.70% |
| BMRN BioMarin Pharmaceutical Inc. compare | 0.73% |
| IBRX ImmunityBio, Inc. compare | 0.00% |
| TWST Twist Bioscience Corporation compare | −30.8% |
| PCVX Vaxcyte, Inc. | −57.3% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −1,480.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)